Novo Nordisk lays off 400 staff in R&D shake-upNovo Nordisk is laying off 400 people in Denmark and China so it can overhaul its R&D and Share XNovo Nordisk lays off 400 staff in R&D shake-uphttps://pharmaphorum.com/news/novo-nordisk-lays-off-400-staff-in-rd-shake-up/
Truvada ruling could allow cheap HIV prevention in the UKCheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people Share XTruvada ruling could allow cheap HIV prevention in the UKhttps://pharmaphorum.com/news/truvada-ruling-could-allow-cheap-hiv-prevention-in-the-uk/
NICE rejects Novartis’ CAR-T in adult lymphomaNICE has said Novartis’ CAR-T therapy Kymriah cannot be funded by the NHS in adults with an aggressive Share XNICE rejects Novartis’ CAR-T in adult lymphomahttps://pharmaphorum.com/news/nice-rejects-novartis-car-t-in-adult-leukaemia/
Finding the roadmap for living with LHONEvery patient faces their own journey through life, learning about their condition with the best tools available to Share XFinding the roadmap for living with LHONhttps://pharmaphorum.com/disease-spotlight/finding-the-roadmap-living-with-lhon/
Digital health round-up: Akili, NVIDIA, Hu-manity.co and moreIn this week’s pharmaphorum digital health round-up we look at Akili’s therapeutic video game, the unveiling of next-gen Share XDigital health round-up: Akili, NVIDIA, Hu-manity.co and morehttps://pharmaphorum.com/views-and-analysis/digital-health-akili-nvidia-humanityco-wannacry/
What next for joint working that really improves patient outcomes?Joint working has become something of the norm in the last decade, but have we taken the time Share XWhat next for joint working that really improves patient outcomes?https://pharmaphorum.com/views-analysis-patients/what-next-joint-working-improves-patient-outcomes/
CAR-Ts – a new weapon in the fight against cancerCAR-T – or Chimeric Antigen Receptor T-cell therapies herald a new wave of therapies in cancer. CAR-T therapies Share XCAR-Ts – a new weapon in the fight against cancerhttps://pharmaphorum.com/views-and-analysis/car-ts-a-new-weapon-in-the-fight-against-cancer/
How to achieve digital success in pharma’s communicationsDemystifying what digital means, empowering people to ‘think digitally’ and acting with confidence are game changing factors for Share XHow to achieve digital success in pharma’s communicationshttps://pharmaphorum.com/views-analysis-digital/achieve-digital-success-pharma/
Future-proofing pharma with a multichannel approach to sales and marketingDeploying a multichannel approach to marketing, backed by the use of advanced analytics, could help pharma evolve and Share XFuture-proofing pharma with a multichannel approach to sales and marketinghttps://pharmaphorum.com/views-analysis-sales-marketing/multichannel-marketing-sales-pharma/
Digital therapeutics and healthcare innovation Share XDigital therapeutics and healthcare innovationhttps://pharmaphorum.com/debates-insight-digital/digital-therapeutics-and-healthcare-innovation/
How to make digital work in medtech Share XHow to make digital work in medtechhttps://pharmaphorum.com/webinars/webinars-on-demand/make-digital-work-medtech/
Engaging with HCPS: what do HCPs want from medical meetings? Share XEngaging with HCPS: what do HCPs want from medical meetings?https://pharmaphorum.com/webinars/webinars-on-demand/engaging-with-hcps-what-do-hcps-want-from-medical-meetings/
The changing face of pharmaceutical launchesThe industry has experienced a sustained period of change since its blockbuster heyday in the 1990s and continues Share XThe changing face of pharmaceutical launcheshttps://pharmaphorum.com/market-access-2/digital-transforming-pharmaceutical-launches/
Remote HCP engagement – still a struggle for life science companiesLife science companies are failing to achieve their full digital potential, particularly when it comes to the use Share XRemote HCP engagement – still a struggle for life science companieshttps://pharmaphorum.com/white-papers/remote-hcps-engagement-life-science/
Medical meetings and what HCPs wantThe healthcare professional (HCP) meeting landscape is evolving, but even as it adjusts to the demands of the Share XMedical meetings and what HCPs wanthttps://pharmaphorum.com/whitepapers/medical-meetings-and-what-hcps-want/
Raising the bar in liver cancer therapy Share XRaising the bar in liver cancer therapyhttps://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s success Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
Part three: Oncology shaping the future of personalised healthcare Share XPart three: Oncology shaping the future of personalised healthcarehttps://pharmaphorum.com/video/part-three-oncology-shaping-future-personalised-healthcare/
Only 4 Weeks Until Orphan Drugs & Rare Diseases 2018 Share XOnly 4 Weeks Until Orphan Drugs & Rare Diseases 2018https://pharmaphorum.com/partner-content/only-4-weeks-until-orphan-drugs-rare-diseases-2018/
Antibiotic Class Emerges through Digestive Enzyme Share XAntibiotic Class Emerges through Digestive Enzymehttps://pharmaphorum.com/partner-content/antibiotic-class-emerges-through-digestive-enzyme-2/
Achieving Controlled Nucleation During Aseptic Lyophilization Share XAchieving Controlled Nucleation During Aseptic Lyophilizationhttps://pharmaphorum.com/partner-content/achieving-controlled-nucleation-during-aseptic-lyophilization/
MHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conference Share XMHRA, Pfizer, Autolus and Tusk Theraputics Sign Up for Immuno-Oncology Conferencehttps://pharmaphorum.com/partner-content/mhra-pfizer-autolus-and-tusk-theraputics-sign-up-for-immuno-oncology-conference/
Carina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitation Share XCarina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitationhttps://pharmaphorum.com/partner-content/carina-schey-university-of-groningen-orphan-drugs-rare-diseases-chair-invitation/
Corporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communications Share XCorporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communicationshttps://pharmaphorum.com/partner-content/corporate-communications-chief-of-astellas-jo-taylor-moves-to-cello-health-communications/
